<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Obstetrics and Gynecology</journal-id><journal-title-group><journal-title xml:lang="en">Obstetrics and Gynecology</journal-title><trans-title-group xml:lang="ru"><trans-title>Акушерство и гинекология</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0300-9092</issn><issn publication-format="electronic">2412-5679</issn><publisher><publisher-name xml:lang="en">Bionika Media</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">462788</article-id><article-id pub-id-type="doi">10.18565/aig.2023.56</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Original Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Оригинальные статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Excess adipose tissue and chronic subclinical inflammation in patients with polycystic ovary syndrome</article-title><trans-title-group xml:lang="ru"><trans-title>Избыток жировой ткани и хроническое субклиническое воспаление при синдроме поликистозных яичников</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3723-5052</contrib-id><name-alternatives><name xml:lang="en"><surname>Kirillova</surname><given-names>Ekaterina D.</given-names></name><name xml:lang="ru"><surname>Кириллова</surname><given-names>Екатерина Дмитриевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Junior Reseasrcher at the Department of Gynecological Endocrinology</p></bio><bio xml:lang="ru"><p>м.н.с. отделения гинекологической эндокринологии</p></bio><email>emiroshina.md@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5023-3476</contrib-id><name-alternatives><name xml:lang="en"><surname>Krechetova</surname><given-names>Lyubov V.</given-names></name><name xml:lang="ru"><surname>Кречетова</surname><given-names>Любовь Валентиновна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Dr. Med. Sci., Head of the Laboratory of Clinical Imunology</p></bio><bio xml:lang="ru"><p>д.м.н., заведующая лабораторией клинической иммунологии</p></bio><email>k_l_v_@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Vtorushina</surname><given-names>Valentina V.</given-names></name><name xml:lang="ru"><surname>Вторушина</surname><given-names>Валентина Валентиновна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>PhD, Immunologist at the Laboratory of Clinical Immunology</p></bio><bio xml:lang="ru"><p>к.м.н., врач лаборатории клинической иммунологии</p></bio><email>v_vtorushina@oparina4.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7990-0276</contrib-id><name-alternatives><name xml:lang="en"><surname>Ivanets</surname><given-names>Tatyana Yu.</given-names></name><name xml:lang="ru"><surname>Иванец</surname><given-names>Татьяна Юрьевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Dr. Med. Sci., Head of the Clinical Diagnostic Laboratory</p></bio><bio xml:lang="ru"><p>д.м.н., заведующая клинико-диагностической лабораторией</p></bio><email>t_ivanets@oparina4.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9065-5689</contrib-id><name-alternatives><name xml:lang="en"><surname>Chernukha</surname><given-names>Galina E.</given-names></name><name xml:lang="ru"><surname>Чернуха</surname><given-names>Галина Евгеньевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Dr. Med. Sci., Professor, Chief Researcher, Department of Gynecological Endocrinology</p></bio><bio xml:lang="ru"><p>д.м.н., профессор, главный н.с. отделения гинекологической эндокринологии</p></bio><email>c-galina1@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Academician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of the Russian Federation</institution></aff><aff><institution xml:lang="ru">ФГБУ «Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии имени академика В.И. Кулакова» Министерства здравоохранения Российской Федерации</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2023-05-30" publication-format="electronic"><day>30</day><month>05</month><year>2023</year></pub-date><issue>4</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>111</fpage><lpage>119</lpage><history><date date-type="received" iso-8601-date="2023-05-29"><day>29</day><month>05</month><year>2023</year></date><date date-type="accepted" iso-8601-date="2023-05-29"><day>29</day><month>05</month><year>2023</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2023, Bionika Media</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2023, ООО «Бионика Медиа»</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="en">Bionika Media</copyright-holder><copyright-holder xml:lang="ru">ООО «Бионика Медиа»</copyright-holder></permissions><self-uri xlink:href="https://journals.eco-vector.com/0300-9092/article/view/462788">https://journals.eco-vector.com/0300-9092/article/view/462788</self-uri><abstract xml:lang="en"><p><bold><italic>Objective:</italic></bold><italic> To analyze the serum levels of proinflammatory markers in patients with polycystic ovary syndrome (PCOS) and assess their association with body composition and metabolic parameters.</italic></p> <p><bold><italic>Materials and methods:</italic></bold><italic> This single-center cross-sectional study included 148 women with PCOS (mean age 25.1 (5.5) years). Of these, 118 had PCOS (mean age 25.1 (5.5) years), 14 were overweight and obese without PCOS (mean age 26.1 (7.4) years) and 16 were somatically healthy women (mean age 25.3 (5.1) years). All participants underwent comprehensive clinical, laboratory, and instrumental examination.</italic></p> <p><bold><italic>Results:</italic></bold><italic> Patients with PCOS had significantly higher levels of IL-6, TNF-</italic><italic>α</italic><italic>, and CRP than those in the control group; however, there were no statistically significant differences in the levels of IL-1, leptin, and adiponectin. PCOS patients had signs of chronic subclinical inflammation in the form of elevated IL-6 and CRP levels in 39% and 37% of the cases, respectively. Hidden obesity was diagnosed in 65.0% of PCOS patients with a normal BMI, manifesting as excess visceral adipose tissue in 46.2% of cases. This group was seven times more likely to have elevated CRP levels and nearly four times more likely to be insulin resistant than patients with normal total body fat percentage.</italic></p> <p><bold><italic>Conclusion: </italic></bold><italic>It is appropriate to recommend adipose tissue densitometry and assessment of levels of proinflammatory markers to identify risk groups for pregnancy complications, cardiovascular disease, and type 2 diabetes mellitus in patients with PCOS with normal BMI and for further correction of modifiable risk factors by lifestyle changes, drug therapy, and pre-pregnancy care.</italic></p></abstract><trans-abstract xml:lang="ru"><p><bold><italic>Цель:</italic></bold><italic> Провести анализ уровней провоспалительных маркеров в сыворотке крови пациенток с синдромом поликистозных яичников (СПКЯ), оценить их связь с композиционным составом тела и метаболическими параметрами.</italic></p> <p><bold><italic>Материалы и методы:</italic></bold><italic> Проведено одноцентровое одномоментное исследование с участием 148 женщин: 118 – с СПКЯ (средний возраст 25,1 (5,5) года), 14 – с избыточной массой тела и ожирением при отсутствии СПКЯ (средний возраст 26,1 (7,4) года) и 16 соматически здоровых женщин (средний возраст 25,3 (5,1) года). Выполнено комплексное клинико-лабораторное и инструментальное обследование.</italic></p> <p><bold><italic>Результаты:</italic></bold><italic> При СПКЯ выявлено значительное повышение уровней интерлейкина-6, фактора некроза опухоли альфа и С-реактивного белка (СРБ) по сравнению с контрольной группой; cтатистически значимых различий по уровням IL-1, лептина и адипонектина не установлено. У пациенток с СПКЯ признаки хронического субклинического воспаления в виде повышения уровней IL-6 и СРБ встречались соответственно в 39 и 37% случаев. При нормальном индексе массы тела (ИМТ) у 65,0% пациенток с СПКЯ диагностировано «скрытое ожирение», в 46,2% случаев проявляющееся избытком висцеральной жировой ткани. В этой группе в 7 раз чаще выявлялось повышение уровня СРБ и почти в 4 раза – инсулинорезистентность, чем у пациенток с нормальным процентом общей жировой ткани.</italic></p> <p><bold><italic>Заключение:</italic></bold><italic> Пациенткам с СПКЯ при нормальном ИМТ целесообразно проводить денситометрию жировой ткани и оценку уровней провоспалительных маркеров для выявления групп риска гестационных осложнений, сердечно-сосудистых заболеваний и сахарного диабета 2-го типа с дальнейшей коррекцией модифицируемых факторов риска путем изменения образа жизни, медикаментозной терапии и прегравидарной подготовки.</italic></p></trans-abstract><kwd-group xml:lang="en"><kwd>polycystic ovarian syndrome</kwd><kwd>BMI</kwd><kwd>chronic subclinical inflammation</kwd><kwd>CRP</kwd><kwd>densitometry</kwd><kwd>body composition</kwd><kwd>visceral obesity</kwd><kwd>metabolic profile</kwd><kwd>insulin resistance</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>синдром поликистозных яичников</kwd><kwd>ИМТ</kwd><kwd>хроническое субклиническое воспаление</kwd><kwd>СРБ</kwd><kwd>денситометрия</kwd><kwd>композиционный состав тела</kwd><kwd>висцеральное ожирение</kwd><kwd>метаболический профиль</kwd><kwd>инсулинорезистентность</kwd></kwd-group><funding-group><funding-statement xml:lang="en">Research work “Clinical and pathogenetic aspects of polycystic ovarian syndrome in relation to the gut microbiota”.</funding-statement><funding-statement xml:lang="ru">Научно-исследовательская работа «Клинико-патогенетические аспекты синдрома поликистозных яичников с учетом микробиоты кишечника».</funding-statement></funding-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Deswal R., Narwal V., Dang A., Pundir C.S. The prevalence of polycystic ovary syndrome: a brief systematic review. J. Hum. Reprod. Sci. 2020; 13(4): 261-71. https://dx.doi.org/10.4103/jhrs.JHRS_95_18.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Goodman N.F., Cobin R.H., Futterweit W., Glueck J.S., Legro R.S., Carmina E.; American Association of Clinical Endocrinologists (AACE); American College of Endocrinology (ACE); Androgen Excess and PCOS Society. American association of clinical endocrinologists, American college of endocrinology, and androgen excess and pcos society disease state clinical review: guide to the best practices in the evaluation and treatment of polycystic ovary syndrome - part 2. Endocr. Pract. 2015; 21(12): 1415-26. https://dx.doi.org/10.4158/ EP15748.DSCPT2.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Zhu S., Li Z., Hu C., Sun F., Wang C., Yuan H. et al. Imaging-based body fat distribution in polycystic ovary syndrome: a systematic review and meta-analysis. Front. Endocrinol. (Lausanne). 2021; 9(12): 697223. https://dx.doi.org/10.3389/fendo.2021.697223.</mixed-citation></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">Chernukha G.E., Miroshina E.D., Kuznetsov S.Yu., Ivanov I.A. Body mass index, body composition, and metabolic profile of patients with polycystic ovary syndrome. Obstetrics and Gynecology. 2021; (10): 103-11. (in Russian). https://dx.doi.org/10.18565/aig.2021.10.103-111.</mixed-citation><mixed-citation xml:lang="ru">Чернуха Г.Е., Мирошина Е.Д., Кузнецов С.Ю., Иванов И.А. Индекс массы тела, композиционный состав тела и метаболический профиль пациенток с синдромом поликистозных яичников. Акушерство и гинекология. 2021; 10: 103-11. https://dx.doi.org/10.18565/aig.2021.10.103-111.</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><mixed-citation>Kelly C.C.J., Lyall H., Petrie J.R., Gould G.W., Connell J.M.C., Sattar N. Low grade chronic inflammation in women with polycystic ovarian syndrome. J. Clin. Endocrinol. Metab. 2001; 86(6): 2453-5. https://dx.doi.org/10.1210/jcem.86.6.7580.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Escobar Morreale H.F., Laque-Ramirez M., Gonzalez F. Circulating inflammatory markers in polycystic ovary syndrome: a systematic review and meta-analysis. Fertil. Steril. 2011; 95(3): 1048-58. https://dx.doi.org/10.1016/ j.fertnstert.2010.11.036.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Mu L., Li R., Lai Y., Zhao Y., Qiao J. Adipose insulin resistance is associated with cardiovascular risk factors in polycystic ovary syndrome. J. Endocrinol. Invest. 2019; 42(5): 541-8. https://dx.doi.org/10.1007/s40618-018-0949-2.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Ramamoorthy S., Bhuvaneswari K. A cross-sectional study on the status of inflammatory markers in polycystic ovary syndrome (PCOS) in Indian population. Biomed. Pharmacol. J. 2019; 12: 1975-83. https://dx.doi.org/10.13005/bpj/1829.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Lin Y.S., Tsai S.J., Lin M.W., Yang C.T., Huang M.F., Wu M.H. Interleukin-6 as an early chronic inflammatory marker in polycystic ovary syndrome with insulin receptor substrate-2 polymorphism. Am. J. Reprod. Immunol. 2011; 66(6): 527-33. https://dx.doi.org/10.1111/j.1600-0897.2011.01059.x.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Fulghesu A.M., Sanna F., Uda S., Magnini R., Portoghese E., Batetta B. IL-6 serum levels and production is related to an altered immune response in polycystic ovary syndrome girls with insulin resistance. Mediators Inflamm. 2011; 2011: 389317. https://dx.doi.org/10.1155/2011/389317.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Borst S.E. The role of TNF-alpha in insulin resistance. Endocrine. 2004; 23(2-3): 177-82. https://dx.doi.org/10.1385/ENDO:23:2-3:177.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Goswami S., Choudhuri S., Bhattacharya B., Bhattacharjee R., Roy A., Mukhopadhyay S. et al. Chronic inflammation in polycystic ovary syndrome: A case-control study using multiple markers. Int. J. Reprod. Biomed. 2021; 19(4): 313-20. https://dx.doi.org/10.18502/ijrm.v19i4.9057.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Choi Y.S., Yang H.I., Cho S., Jung J.A., Jeon Y.E., Kim H.Y. et al. Serum asymmetric dimethylarginine, apelin, and tumor necrosis factor-α levels in non-obese women with polycystic ovary syndrome. Steroids. 2012; 77(13): 1352-8. https://dx.doi.org/10.1016/j.steroids.2012.08.005.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>De Luca C., Olefsky J.M. Inflammation and insulin resistance. FEBS Lett. 2008; 582: 97-105. https://dx.doi.org/10.1016/j.febslet.2007.11.057.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Shoelson S.E., Lee J., Goldfine A.B. Inflammation and insulin resistance. J. Clin. Invest. 2006; 116(7): 1793-801. https://dx.doi.org/10.1172/JCI29069.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Zatterale F., Longo M., Naderi J., Raciti G.A., Desiderio A., Miele C. et al. Chronic adipose tissue inflammation linking obesity to insulin resistance and Type 2 diabetes. Front. Psychol. 2020; 10: 1607. https://dx.doi.org/10.3389/fphys.2019.01607.</mixed-citation></ref><ref id="B17"><label>17.</label><citation-alternatives><mixed-citation xml:lang="en">Ministry of Health of Russian Federation. Clinical guidelines "Polycystic ovary syndrome". Moscow; 2021. (in Russian).</mixed-citation><mixed-citation xml:lang="ru">Министерство здравоохранения Российской Федерации. Синдром поликистозных яичников. Клинические рекомендации М.; 2021.</mixed-citation></citation-alternatives></ref><ref id="B18"><label>18.</label><mixed-citation>Sumner A.E., Cowie C.C. Ethnic differences in the ability of triglyceride levels to identify insulin resistance. Atherosclerosis. 2008; 196(2): 696-703. https://dx.doi.org/10.1016/j.atherosclerosis.2006.12.018.</mixed-citation></ref><ref id="B19"><label>19.</label><citation-alternatives><mixed-citation xml:lang="en">Ministry of Health of Russian Federation. Clinical guidelines "Type 2 diabetes in adults". Moscow; 2019. (in Russian).</mixed-citation><mixed-citation xml:lang="ru">Министерство здравоохранения Российской Федерации. Сахарный диабет 2 типа у взрослых. Клинические рекомендации М.; 2019.</mixed-citation></citation-alternatives></ref><ref id="B20"><label>20.</label><mixed-citation>Sim S.J., Park H.S. The cut-off values of body fat to identify cardiovascular risk among Korean adults. Korean J. Obes. 2004; 13(1): 14-21.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Dudeja V., Misra A., Pandey R.M., Devina G., Kumar G., Vikram N.K. BMI does not accurately predict overweight in Asian Indians in northern India. Br. J. Nutr. 2001; 86(1): 105-12. https://dx.doi.org/10.1079/bjn2001382.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Goh V.H., Tain C.F., Tong T.Y., Mok H.P., Wong M.T. Are BMI and other anthropometric measures appropriate as indices for obesity? A study in an Asian population. J. Lipid Res. 2004; 45(10): 1892-8. https://dx.doi.org/10.1194/ jlr.M400159-JLR200.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Miazgowski T., Krzyżanowska-Świniarska B., Dziwura-Ogonowska J., Widecka K. The associations between cardiometabolic risk factors and visceral fat measured by a new dual-energy X-ray absorptiometry-derived method in lean healthy Caucasian women. Endocrine. 2014; 47(2): 500-5. https://dx.doi.org/10.1007/s12020-014-0180-7.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Palomba S., de Wilde M.A., Falbo A., Koster M.P., La Sala G.B., Fauser B.C. Pregnancy complications in women with polycystic ovary syndrome. Hum. Reprod. Update. 2015; 21(5): 575-92. https://dx.doi.org/10.1093/humupd/dmv029.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Abraham Gnanadass S., Divakar Prabhu Y., Valsala Gopalakrishnan A. Association of metabolic and inflammatory markers with polycystic ovarian syndrome (PCOS): an update. Arch. Gynecol. Obstet. 2021; 303(3): 631-43. https://dx.doi.org/10.1007/s00404-020-05951-2.</mixed-citation></ref><ref id="B26"><label>26.</label><citation-alternatives><mixed-citation xml:lang="en">Yureneva S.V., Komedina V.I., Kuznetsov S.Yu. Diagnostic value of anthropometric characteristics of obesity in women during the menopause transition. Obstetrics and Gynecology. 2022; (2): 72-9. (in Russian). https://dx.doi.org/10.18565/aig.2022.2.72-79.</mixed-citation><mixed-citation xml:lang="ru">Юренева С.В., Комедина В.И., Кузнецов С.Ю. Диагностические возможности антропометрических показателей для оценки ожирения у женщин в период менопаузального перехода. Акушерство и гинекология. 2022; 2: 72-9. https://dx.doi.org/10.18565/aig.2022.2.72-79.</mixed-citation></citation-alternatives></ref><ref id="B27"><label>27.</label><mixed-citation>Aboeldalyl S., James C., Seyam E., Ibrahim E.M., Shawki H.E., Amer S. The role of chronic inflammation in polycystic ovarian syndrome-a systematic review and meta-analysis. Int. J. Mol. Sci. 2021; 22(5): 2734. https://dx.doi.org/10.3390/ijms22052734.</mixed-citation></ref><ref id="B28"><label>28.</label><citation-alternatives><mixed-citation xml:lang="en">Chernukha G.E., Blinova I.V. PCOS: cardiovascular risks and the impact of siofor therapy on them. Difficult Patient. 2008; 6(1): 18-22 (in Russian).</mixed-citation><mixed-citation xml:lang="ru">Чернуха Г.Е., Блинова И.В. СПКЯ: кардиоваскулярные риски и влияние на них терапии сиофором. Трудный пациент. 2008; 6(1): 18-22.</mixed-citation></citation-alternatives></ref><ref id="B29"><label>29.</label><mixed-citation>Palomba S., Falbo A., Chiossi G., Orio F., Tolino A., Colao A. et al. Low-grade chronic inflammation in pregnant women with polycystic ovary syndrome: a prospective controlled clinical study. J. Clin. Endocrinol. Metab. 2014; 99(8): 2942-51. https://dx.doi.org/10.1210/jc.2014-1214.</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Mukherjee A.G., Wanjari U.R., Kannampuzha S., Murali R., Namachivayam A., Ganesan R. et al. The implication of mechanistic approaches and the role of the microbiome in polycystic ovary syndrome (PCOS): a review. Metabolites. 2023; 13: 129. https://dx.doi.org/10.3390/metabo13010129.</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Custodero C., Mankowski R.T., Lee S.A., Chen Z., Wu S., Manini T.M. et al. Evidence-based nutritional and pharmacological interventions targeting chronic low-grade inflammation in middle-age and older adults: A systematic review and meta-analysis. Ageing Res. Rev. 2018; 46: 42-59. https://dx.doi.org/10.1016/ j.arr.2018.05.004.</mixed-citation></ref></ref-list></back></article>
